OmniPathology Presents at HPV Masterclass
Advancing Awareness and Early Detection of HPV-Related Throat Cancer
OmniPathology was honored to participate in the Institute of Women’s Health and Integrative Medicine Master Class on HPV, which focused on the latest advancements in detecting human papillomavirus (HPV) infections, HPV-associated cancers, and emerging strategies for prevention and early detection.
The two-day educational program brought together physicians, scientists, and healthcare leaders to discuss the growing public health impact of HPV-related disease.
The Rising Epidemic of HPV-Related Throat Cancer
During the symposium, Dr. Mohammad Kamal, CEO of OmniPathology, presented on the alarming rise of HPV-associated oropharyngeal (throat) cancer and anal cancer. Both cancers are caused primarily by the same high-risk HPV viruses known to cause cervical cancer.
While cervical cancer rates have declined significantly over the past several decades due to routine Pap testing and HPV screening, HPV-related throat cancer continues to increase dramatically in the United States. In fact, there are now approximately twice as many cases of HPV-related throat cancer diagnosed annually in the U.S. as cervical cancer.
Dr. Kamal emphasized the importance of awareness and proactive screening for patients at increased risk of HPV infection and persistent disease.
Who May Be at Increased Risk?
Individuals who may be at higher risk for persistent HPV infection include:
People with multiple lifetime sexual partners
Partners of individuals known to be HPV-positive
Patients with a history of cervical HPV infection
Immunocompromised individuals, including patients with HIV, cancer, or those taking immunosuppressive medications
Research has shown that partners of women with cervical HPV infection may have an increased risk of acquiring oral HPV infection. Additionally, women with cervical HPV may also be at increased risk for anal HPV infection due to anatomic proximity and viral transmission patterns.
Although the Gardasil vaccine provides protection against several of the most common high-risk HPV types, there are 14 recognized high-risk HPV strains associated with cancer development. As a result, screening remains an important component of risk assessment and early detection.
OmniPathology’s Proprietary OP2 HPV™ Screening Assay
As part of the symposium, Dr. Ronald Blum, Vice President of Science and Technology at OmniPathology, along with Krista Grinstead, Business Development Specialist, presented OmniPathology’s proprietary and patent-pending OP2 HPV™ assay for detecting high-risk oropharyngeal HPV infection.
The OP2 HPV™ test was developed to provide a straightforward, painless, and non-invasive method for identifying persistent oral HPV infection — the key factor associated with increased cancer risk.
Most HPV infections of the throat resolve spontaneously within one to two years. However, approximately 30% of infections may persist, potentially increasing the risk for the development of cancer over time.
Simple Collection. Advanced Molecular Testing.
The OP2 HPV™ collection kit contains a specialized swab designed to collect cells from the tonsils and posterior throat. The sample is placed into viral transport media and sent to OmniPathology for highly sensitive real-time PCR analysis.
The assay detects all 14 high-risk HPV types associated with cancer and offers:
95% sensitivity
100% specificity
Room temperature specimen stability for up to two weeks
Convenient collection in physician offices and clinics
The test is covered by Medicare and many commercial insurance plans.
The Importance of Early Detection and Surveillance
Currently, there are no standardized national screening guidelines for oropharyngeal HPV. OmniPathology recommends that sexually active adults, particularly those with increased risk factors, consider annual screening for high-risk oral HPV infection.
This proactive approach of testing and retesting positive patients is aimed at identifying individuals with persistent throat HPV infection. These patients are at a higher risk of developing throat cancer and would benefit from referral to Ear, Nose, and Throat (ENT) specialists for comprehensive evaluation and ongoing surveillance. Early detection of abnormal changes is critical for improving outcomes and saving lives.
As awareness of HPV-related throat cancer continues to grow, OmniPathology remains committed to advancing innovative molecular diagnostics that help clinicians identify risk earlier and provide patients with proactive, personalized care.
